Safety and tolerability of the new phosphodiesterase inhibitor (B9302-107) administered to healthy male volunteers as ascending repeated oral doses over 7 days

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A single-blind, placebo-controlled, four-period study in healthy male subjects.